why choose us

First received: May 22, 2023

Clinical Trial: A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)

Study Status: Completed

Recruit Status: RECRUITING

Condition: PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)

Study Type: INTERVENTIONAL


Official Title: A Phase 1 Dose Escalation Trial Evaluating an Intravenously Administered Recombinant Adeno-Associated Virus Serotype rh.74 (AAVrh.74) Vector Containing the Human Plakophilin-2a (PKP2a) Coding Sequence

Brief Summary: This Phase 1 dose escalation trial will assess the safety and preliminary efficacy of a single dose intravenous infusion of RP-A601 in high-risk adult patients with PKP2-ACM.

Read more